BPC-157 vs LL-37: Healing Peptides Compared
Written by NorthPeptide Research Team | Reviewed December 10, 2025
Two peptides appear again and again in healing and recovery research: BPC-157 and LL-37. Both are studied for their ability to support tissue repair and reduce damage. But they are very different molecules with different targets, different mechanisms, and different strengths.
What Is BPC-157?
BPC-157 stands for Body Protection Compound-157. It is a synthetic peptide derived from a protein sequence found naturally in human gastric juice. That origin tells you something about its design — it appears to have evolved to protect tissue in one of the harshest environments in the body.
In research, BPC-157 has been studied for its effects on:
- Tendon and ligament repair
- Muscle healing after injury
- Gut inflammation and ulcer healing
- Nerve regeneration
- Blood vessel formation (angiogenesis)
It appears to work partly by activating growth hormone receptors and by promoting the growth of new blood vessels into damaged tissue. Both of these are essential for efficient healing.
What Is LL-37?
LL-37 is very different. It is a cathelicidin antimicrobial peptide — a type of peptide your immune system naturally produces. It is found in white blood cells and on mucosal surfaces like the lining of your lungs and gut. Its original job is to kill bacteria and viruses directly by disrupting their membranes.
But LL-37 does more than fight infection. Research has shown it also:
- Promotes wound closure and skin regeneration
- Modulates immune responses
- Stimulates blood vessel growth
- Has anti-biofilm properties (breaks up bacterial colonies)
- May play a role in cancer cell signaling — a complex and actively studied area
Head-to-Head: Where Each Peptide Stands Out
Musculoskeletal Healing
BPC-157 wins here by a wide margin. The bulk of published research on BPC-157 involves tendons, ligaments, muscles, and bones. Studies in rodents consistently show accelerated healing rates compared to controls. LL-37 has not been significantly studied for muscle or tendon repair.
Wound Healing and Skin Repair
Both peptides have research here, but they work differently. BPC-157 promotes healing through growth factor activation and angiogenesis. LL-37 promotes wound closure through immune modulation and direct stimulation of skin cell migration. Some researchers have proposed using both together for complex wound management.
Gut and Mucosal Health
BPC-157 is the clear leader for gut-related research. Dozens of studies in rats and mice show it accelerates healing of gastric ulcers, reduces gut inflammation, and protects intestinal tissue from damage. LL-37, while naturally present in the gut lining, has less research specifically on gut repair.
Immune Defense
LL-37 dominates here. Its primary role is antimicrobial — it can directly kill bacteria and viruses and coordinate the immune response. BPC-157 has some anti-inflammatory effects, but it does not have antimicrobial properties.
Inflammation Modulation
Both peptides have anti-inflammatory properties, but through different pathways. BPC-157 appears to act on nitric oxide and growth hormone signaling. LL-37 modulates cytokine production and immune cell recruitment.
Are They Studied Together?
There is emerging interest in combining peptides with complementary mechanisms. BPC-157 and LL-37 could theoretically work together — BPC-157 promoting tissue scaffold rebuilding while LL-37 manages immune responses and prevents infection in the healing environment. However, no published studies have directly compared or combined them for the same indication.
Research Limitations
Both peptides have significant gaps in their research profiles. Most studies are rodent models. Human trials are limited. Long-term safety data is sparse. Optimal dosing and delivery routes are not established for humans. LL-37’s role in cancer biology is complex and not fully understood — some research shows it may promote cancer cell growth in certain contexts.
Explore Research Peptides
Browse NorthPeptide’s full catalog of third-party tested research compounds.
Summary of Key Research References
| PMID | Authors | Year | Key Finding |
|---|---|---|---|
| 25431020 | Sikiric et al. | 2014 | BPC-157 demonstrated broad tissue-protective effects across musculoskeletal and gut models |
| 18710827 | Koczulla et al. | 2003 | LL-37 promoted angiogenesis and wound healing in rodent skin models |
| 22761575 | Vandamme et al. | 2012 | LL-37 modulated immune cell recruitment and reduced bacterial biofilm formation in wound models |
| 30669748 | Gwyer et al. | 2019 | BPC-157 promoted tendon healing via growth factor upregulation in rodent models |
Written by the NorthPeptide Research Team